We are live on ! Find out more
CNSP icon

CNS Pharmaceuticals
CNSP

13 hedge funds and large institutions have $297K invested in CNS Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 2

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

295% more capital invested

Capital invested by funds: $75.3K → $297K (+$222K)

86% more funds holding

Funds holding: 7 → 13 (+6)

0% more ownership

Funds ownership: 0% → 0.01% (+0%)

Holders
13
Holders Change
+6
Holders Change %
+85.71%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
4
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$47K
2
Citadel Advisors
Citadel Advisors
Florida
+$38.1K
3
XT
XTX Topco
Cayman Islands
+$35K
4
CCM
Connective Capital Management
California
+$33.2K
5
IWC
Integrated Wealth Concepts
Massachusetts
+$29.7K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$13.9K
2
TRCT
Tower Research Capital (TRC)
New York
-$2.13K
3
APC
Aspire Private Capital
North Carolina
-$52
Name Holding Trade Value Shares
Change 		Change in
Stake
Jane Street
1
Jane Street
New York
$50.5K +$47K +661 +1,695%
Geode Capital Management
2
Geode Capital Management
Massachusetts
$46.6K +$21.8K +306 +90%
Citadel Advisors
3
Citadel Advisors
Florida
$38.8K +$38.1K +536 New
XT
4
XTX Topco
Cayman Islands
$35.5K +$35K +492 New
CCM
5
Connective Capital Management
California
$33.7K +$33.2K +467 New
IWC
6
Integrated Wealth Concepts
Massachusetts
$30.1K +$29.7K +417 New
VF
7
Virtu Financial
New York
$20K +$4.69K +66 +32%
HF
8
HRT Financial
New York
$18K +$18.5K +260 New
Two Sigma Investments
9
Two Sigma Investments
New York
$11.2K +$11K +155 New
UBS Group
10
UBS Group
Switzerland
$7.73K -$13.9K -196 -65%
Goldman Sachs
11
Goldman Sachs
New York
$4.86K +$1.42K +20 +43%
MCM
12
MAI Capital Management
Ohio
$241 +$213 +3 New
Bank of America
13
Bank of America
North Carolina
$53 +$71 +1 New
SS
14
SBI Securities
Japan
$13 – – –
SIM
15
Synergy Investment Management
Florida
$1 – – –
TRCT
16
Tower Research Capital (TRC)
New York
– -$2.13K -27 Closed
APC
17
Aspire Private Capital
North Carolina
– -$52 -1 Closed

CNSP Hedge Fund Activity: Q4 2024 in Review

13 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in CNS Pharmaceuticals (CNSP) for Q4 2024, worth a combined $297K — up 295% from $75.3K a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new CNSP positions and 2 closed out — a net gain of 6 holders — while 4 added to existing stakes and 1 trimmed.

The largest buyer was Jane Street, adding an estimated $47K. The largest seller was UBS Group, cutting an estimated $13.9K.

  • 13 institutional investors held CNS Pharmaceuticals (CNSP) as of Q4 2024, up from 7 in Q3 2024.
  • Funds reported $297K of CNS Pharmaceuticals stock for Q4 2024, up 295% quarter-over-quarter.
  • 8 funds opened new CNS Pharmaceuticals positions in Q4 2024 and 2 closed out, a net change of +6 holders.
  • The largest CNS Pharmaceuticals buyer in Q4 2024 was Jane Street, an estimated $47K added.
  • The largest CNS Pharmaceuticals seller in Q4 2024 was UBS Group, an estimated $13.9K sold.

Based on aggregated 13F filings for Q4 2024.